Physician profile
John A Arledge
NPI 1639249675
$7,332.33
in general payments reported to CMS, 2019-2025
43 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $419 · 2021: $1,236 · 2022: $985 · 2023: $1,068 · 2024: $1,156 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,479.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,085.18 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,209.64 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $365.08 | 2019-2025 | Stelara, Remicade, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $358.19 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $320.24 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $276.37 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $221.36 | 2019-2025 | Exalt Model D, General - Therapies |
| Intercept Pharmaceuticals, INC. | $191.48 | 2020-2024 | Ocaliva |
| Enterra Medical, INC. | $183.99 | 2023-2025 | |
| Pfizer INC. | $179.80 | 2019-2025 | |
| Allergan, INC. | $168.68 | 2019 | |
| Celgene Corporation | $166.30 | 2022-2023 | Zeposia |
| Lilly USA, LLC | $145.10 | 2023-2025 | Omvoh |
| Covidien Lp | $144.41 | 2019 | |
| Endogastric Solutions, INC | $124.99 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Arledge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.